PL3837258T3 - Amidy dimetyloaminoazetydyny jako inhibitory jak - Google Patents

Amidy dimetyloaminoazetydyny jako inhibitory jak

Info

Publication number
PL3837258T3
PL3837258T3 PL19769674.3T PL19769674T PL3837258T3 PL 3837258 T3 PL3837258 T3 PL 3837258T3 PL 19769674 T PL19769674 T PL 19769674T PL 3837258 T3 PL3837258 T3 PL 3837258T3
Authority
PL
Poland
Prior art keywords
dimethyl amino
jak inhibitors
amino azetidine
amides
azetidine amides
Prior art date
Application number
PL19769674.3T
Other languages
English (en)
Inventor
Daniel D. Long
Cameron Smith
Corbin Thompson
Original Assignee
Theravance Biopharma R&D Ip, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip, Llc filed Critical Theravance Biopharma R&D Ip, Llc
Publication of PL3837258T3 publication Critical patent/PL3837258T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL19769674.3T 2018-09-04 2019-09-03 Amidy dimetyloaminoazetydyny jako inhibitory jak PL3837258T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862726562P 2018-09-04 2018-09-04
PCT/US2019/049276 WO2020051105A1 (en) 2018-09-04 2019-09-03 Dimethyl amino azetidine amides as jak inhibitors

Publications (1)

Publication Number Publication Date
PL3837258T3 true PL3837258T3 (pl) 2024-09-16

Family

ID=67982186

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19769674.3T PL3837258T3 (pl) 2018-09-04 2019-09-03 Amidy dimetyloaminoazetydyny jako inhibitory jak

Country Status (27)

Country Link
US (4) US10947229B2 (pl)
EP (1) EP3837258B1 (pl)
JP (2) JP7324836B2 (pl)
KR (1) KR102826491B1 (pl)
CN (1) CN112739697B (pl)
AR (1) AR116115A1 (pl)
AU (1) AU2019336167B2 (pl)
BR (1) BR112021004052A2 (pl)
CL (1) CL2021000514A1 (pl)
CO (1) CO2021002977A2 (pl)
DK (1) DK3837258T3 (pl)
EA (1) EA202190681A1 (pl)
ES (1) ES2982858T3 (pl)
FI (1) FI3837258T3 (pl)
HR (1) HRP20241002T1 (pl)
HU (1) HUE068058T2 (pl)
IL (1) IL281146B2 (pl)
LT (1) LT3837258T (pl)
MA (1) MA53229A (pl)
MX (1) MX2021002521A (pl)
PH (1) PH12021550368A1 (pl)
PL (1) PL3837258T3 (pl)
PT (1) PT3837258T (pl)
SG (1) SG11202101734RA (pl)
SI (1) SI3837258T1 (pl)
TW (1) TWI791886B (pl)
WO (1) WO2020051105A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10100049B2 (en) 2015-11-03 2018-10-16 Theravance Biopharma R&D Ip, Llc JAK kinase inhibitor compounds for treatment of respiratory disease
CN110461839B (zh) 2017-03-09 2022-08-23 施万生物制药研发Ip有限责任公司 含有4元杂环酰胺的jak抑制剂
PL3837258T3 (pl) * 2018-09-04 2024-09-16 Theravance Biopharma R&D Ip, Llc Amidy dimetyloaminoazetydyny jako inhibitory jak
EA202190686A1 (ru) 2018-09-04 2021-07-23 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи 5-7-членные гетероциклические амиды в качестве ингибиторов jak
MX2021002273A (es) 2018-09-04 2021-05-27 Theravance Biopharma R&D Ip Llc Proceso para preparar inhibidores de las jak y productos intermedios de estos.
TW202144343A (zh) * 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
WO2021226637A1 (en) * 2020-05-08 2021-11-11 Theravance Biopharma R&D Ip, Llc Method of treating a patient infected with a coronavirus with nezulcitinib
WO2022271604A1 (en) 2021-06-21 2022-12-29 Theravance Biopharma R&D Ip, Llc Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l
CA3223194A1 (en) * 2021-06-25 2022-12-29 Theravance Biopharma R&D Ip, Llc Imidazolo indazole compounds as jak inhibitors
TWI876245B (zh) * 2021-12-17 2025-03-11 南韓商大熊製藥股份有限公司 (2R, 3S)-2-(3-(4,5-二氯-1H-苯并[d]咪唑-1-基)丙基)哌啶-3-醇的新穎酸加成鹽及晶形
CN119403552A (zh) * 2022-05-05 2025-02-07 施万生物制药研发Ip有限责任公司 用于通过雾化口腔吸入递送的奈珠西替尼
WO2023230236A1 (en) 2022-05-26 2023-11-30 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
AU2004259012C1 (en) 2003-07-23 2012-08-02 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ttk阻害作用を有するインダゾール誘導体
JP5651681B2 (ja) 2009-04-03 2015-01-14 大日本住友製薬株式会社 代謝型グルタミン酸受容体5介在障害の治療のための化合物、およびその使用方法
CN102821607B (zh) 2009-12-21 2014-12-17 萨穆梅德有限公司 1H-吡唑并[3,4-b]吡啶及其治疗应用
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
MA39092B1 (fr) 2013-12-05 2018-09-28 Pfizer Pyrrolo[2,3-d]pyrimidinyle, pyrrolo[2,3-b]pyrazinyle et pyrollo[2,3-d]pyridinyle acrylamides
SG11201609139WA (en) 2014-05-14 2016-11-29 Pfizer Pyrazolopyridines and pyrazolopyrimidines
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
US10100049B2 (en) 2015-11-03 2018-10-16 Theravance Biopharma R&D Ip, Llc JAK kinase inhibitor compounds for treatment of respiratory disease
EP3371185B1 (en) 2015-11-03 2020-09-30 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
DK3712152T3 (da) 2015-11-03 2021-03-22 Topivert Pharma Ltd 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus kinase-inhibitorer
CN110461839B (zh) * 2017-03-09 2022-08-23 施万生物制药研发Ip有限责任公司 含有4元杂环酰胺的jak抑制剂
US20180258546A1 (en) 2017-03-09 2018-09-13 Lam Research Corporation Electroplating apparatus and methods utilizing independent control of impinging electrolyte
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
JP7096268B2 (ja) 2017-05-01 2022-07-05 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jak阻害剤化合物の結晶形態
CA3059785A1 (en) 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Methods of treatment using a jak inhibitor compound
CN112566713A (zh) 2018-07-20 2021-03-26 波里费拉公司 具有再循环回路的渗透模块
PL3837258T3 (pl) 2018-09-04 2024-09-16 Theravance Biopharma R&D Ip, Llc Amidy dimetyloaminoazetydyny jako inhibitory jak
MX2021002273A (es) 2018-09-04 2021-05-27 Theravance Biopharma R&D Ip Llc Proceso para preparar inhibidores de las jak y productos intermedios de estos.
EA202190686A1 (ru) * 2018-09-04 2021-07-23 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи 5-7-членные гетероциклические амиды в качестве ингибиторов jak
AU2019373059A1 (en) 2018-10-29 2021-05-06 Theravance Biopharma R&D Ip, Llc 2-azabicyclo hexane compound as JAK inhibitor
HRP20240994T1 (hr) 2019-02-25 2024-10-25 Henan Medinno Pharmaceutical Technology Co., Ltd. Spoj inhibitora jak i njegova uporaba
KR20210137087A (ko) 2019-03-05 2021-11-17 인사이트 코포레이션 만성 폐 동종이식 기능장애의 치료를 위한 jak1 경로 억제제
CN112279848A (zh) 2019-07-25 2021-01-29 四川海思科制药有限公司 一种泛JAKs抑制剂及其用途
TW202144343A (zh) * 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
WO2021226637A1 (en) 2020-05-08 2021-11-11 Theravance Biopharma R&D Ip, Llc Method of treating a patient infected with a coronavirus with nezulcitinib
WO2022178215A1 (en) 2021-02-19 2022-08-25 Theravance Biopharma R&D Ip, Llc Amino amide tetrahydro imidazo pyridines as jak inhibitors
US20220306626A1 (en) 2021-03-26 2022-09-29 Theravance Biopharma R&D Ip, Llc Crystalline form of a dihydrochloride salt of a jak inhibitor compound
WO2022271604A1 (en) * 2021-06-21 2022-12-29 Theravance Biopharma R&D Ip, Llc Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l

Also Published As

Publication number Publication date
IL281146A (en) 2021-04-29
US20250034131A1 (en) 2025-01-30
PH12021550368A1 (en) 2022-03-28
BR112021004052A2 (pt) 2021-05-25
AU2019336167B2 (en) 2024-08-29
TW202024073A (zh) 2020-07-01
IL281146B2 (en) 2023-12-01
CO2021002977A2 (es) 2021-05-31
PT3837258T (pt) 2024-06-20
MA53229A (fr) 2022-05-11
WO2020051105A1 (en) 2020-03-12
SI3837258T1 (sl) 2024-09-30
US11634419B2 (en) 2023-04-25
ES2982858T3 (es) 2024-10-17
JP7324836B2 (ja) 2023-08-10
EA202190681A1 (ru) 2021-05-28
HUE068058T2 (hu) 2024-12-28
IL281146B1 (en) 2023-08-01
SG11202101734RA (en) 2021-03-30
FI3837258T3 (fi) 2024-05-27
JP2021535177A (ja) 2021-12-16
TWI791886B (zh) 2023-02-11
MX2021002521A (es) 2021-04-28
AU2019336167A1 (en) 2021-03-11
LT3837258T (lt) 2024-05-27
CL2021000514A1 (es) 2021-07-23
DK3837258T3 (da) 2024-07-22
US12398135B2 (en) 2025-08-26
AR116115A1 (es) 2021-03-31
US20200071323A1 (en) 2020-03-05
KR20210056381A (ko) 2021-05-18
EP3837258B1 (en) 2024-04-24
US20230322774A1 (en) 2023-10-12
CN112739697B (zh) 2023-10-20
HRP20241002T1 (hr) 2024-10-25
CN112739697A (zh) 2021-04-30
JP2022172299A (ja) 2022-11-15
US10947229B2 (en) 2021-03-16
KR102826491B1 (ko) 2025-06-27
EP3837258A1 (en) 2021-06-23
US20210155620A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
IL281146A (en) Dimethyl amino aztidine amides as JAK inhibitors
IL268625A (en) Amino pyrimidine compounds used as SSAO inhibitors
IL282460A (en) The compound 2-azabicyclohexane as a JAK inhibitor
GB201915593D0 (en) Hand-held integral aribrush
CA193496S (en) Screwdriver
IL287876A (en) Jak inhibitors
IL275374A (en) Pyrrolidine amides I are converted
IL289266A (en) new molecules
CA192878S (en) Brush stand
GB201708390D0 (en) Novel alpha-amino amide derivatives
EP3873473A4 (en) Aminoazine amides
IL291611A (en) Jak inhibitors
IL289773A (en) Disubstituted amino triazoles are useful as chitinase inhibitors
GB2601449B (en) Key-compressible encryption
GB201818629D0 (en) Compositions comprising amino acids
IL290381A (en) Jak inhibitors
HK40048449A (en) Dimethyl amino azetidine amides as jak inhibitors
GB201914325D0 (en) Novel meethod
CA190942S (en) Screw head
HUE058883T2 (hu) Levél-eltávolító fej
ZA202201899B (en) Substituted amino triazoles useful as chitinase inhibitors
GB201918693D0 (en) Peptide
GB201912632D0 (en) Peptide
GB201913320D0 (en) Novel proteins
GB201919193D0 (en) Novel molecules